HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies 478P TA-ness AACR2023 ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis angiosarcoma Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR aplastic anemia AA apoptosis Apoptosis appendiceal neoplasms Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells B-accute lyphoblastic leukemia B-ALL B-accute lyphoblastic seukemia B-ALL B-cell lymphoma bacterial vaginosis BCL2A1 BCL6 benign bile acids Biofluid Biology of neoplasia Biomarker biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers biomarkers Bladder Bladder cancer Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blastoid morphology blindness Blood bone Brain breast cancer Breast Cancer Breast milk Breast Milk Burkitt lymphoma cancer genetics Cancer Genomics cancer therapy CAR T cell therapy CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDK CDK46 inhibitors CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid cervix Cetuximab Chemokines chemotherapy Childhood Atopic Dermatitis children chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications clinical trial Clinical Trial cMET cognition cold tumor Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA custom panel CXCL12 cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity Dementia dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug sensitivity Drug Targets Drug-induced Liver Injury dysbiosis Dysplasia ear Efficacy EGFR Muatations EHE cancer EMT Encephalophy end stage kidney disease Endothelial cell EPCORE NHL-1 epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epithelial–mesenchymal plasticity Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors estrogen receptor 1 ESR1 exosome Exosomes extracellular miRNAs Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease farnesoid X receptorcholesterol Feasibility female reproductive tract FFPE FGF Ligand Trap FGFR fibroblast growth factor receptor 4 Fibrous Tumors FOLFOX7 Follicular lymphoma gastrointestinal cancer GEIS Gene Expression gene expression Gene expression analysis gene expression profiling Gene Expression Profiling gene expression signature Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors glucocorticoid receptor NR3C1 HARMONIA clinical trial HCC Head and neck cancer Head and Neck Cancer Heart hematologic or solid tumors hepatocellular carcinoma HER HER-2 HER2 HER2- Heterogeneity Histone Deacetylase Inhibitors histone methyltransferase HLA-E Homing hot tumor HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC immunoscore Immunotherapy immunotherapy Inflammation inhibitor Insulin Resistance Integrins Intrinsic subtypes inverted papilloma IOA- 244 IOA-244 IRF4 IRP IRS-1 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Lactobacillus crispatus LAG3+ Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy Liver liver liver disease liver steatosis liver tissue Lung Lung cancer lungs Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia Lymphoma lymphoma lymphomas Machine Learning machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma melanoma Mesothelioma MET metastatic breast cancer MBC metastatic colorectal cancer CRC Method Comparison MIBC Microenvironment MicroRNA microRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization molecular subtypes Mouse Mouse mRNA mouse mRNA TRP mRNA mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma multiple myeloma MUM1 Muscle Muscle-invasive bladder cancer mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Nature Neoantigens Nestin+ Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgink Lymphoma non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay Obesity obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral cavity Oral lesion Oral Squamous Cell Carcinoma oral squamous cell carcinoma Oropharyngeal Cancer OSCC Osteoarthritis Osteoclast Ovarian cancer palbociclib PALLET PALOMA PALOMA-2 PAM50 Predictive biomarkers Pan-Cancer PanB Pancreas Pancreatic Cancer pancreatic ductal adenocarcinoma PDAC Paralysis Parkinson's Disease Partial EMT Pathogenesis pathophysiology Pathway Analysis Pathway analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PDX model PEARL PENELOPE-B PFAS PFNA PFOS Phase III PHOENIX trial PI3K PI3K inhibitors PIK3CA mutation PIP placenta Placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine Precision oncology predictive biology Predictive Biomarkers Predictive Modeling Prevotella bivia Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR R-CHOP race disparities Radioimmunotherapy RAS Rbsig Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma renal cell carcinoma Renal Disease Reproductive Response rate RET Reveal Rhabdomyosarcoma RMS Rheumatoid Arthritis Risk Score ROS1 safety sarcoma Sarcoma SARS-CoV-2 scoring system Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Single-cell RNA Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium Squamous cell carcinoma squamous cell carcinoma STAT6 pathway STD Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T cells T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer Tislelizumab tislelizumab TMB TME tomentosin Toxicity TP53 mutation transcriptome Transcriptome transcriptome profile transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Trichomonas vaginalis Triple Negative Breast CancerTNBC Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma Uterus vagina VEGFR vestibular schwannoma VS virus Waldeyer's ring Wound healing Xenograft Tissue Zanubrutinib Zanubrutinlb ZEB1

2019

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Hicks, S. W., et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hematologica. 2019 Feb 7; 104(8):1633-1639

Download pdf 1.5MB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial

Richter, J.  et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Poster Presented at: ASH Annual meeting session 626. 2018 Dec 3. San Diego, CA

Download pdf 1.1MB
View External Link

Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial

Richter, J. et al, Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany Abstract, #AG02.16

Download pdf 121KB

PQR309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy.

Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].

PMID: 29066507

View External Link

2017

Page last updated May 22, 2023